QMasters Medical Informatics Ltd 08327861 false 2024-01-01 2025-03-31 2025-03-31 The principal activity of the company is that of a holding company. Digita Accounts Production Advanced 6.30.9574.0 true true 08327861 2024-01-01 2025-03-31 08327861 2025-03-31 08327861 bus:OrdinaryShareClass1 2025-03-31 08327861 bus:OrdinaryShareClass2 2025-03-31 08327861 bus:OrdinaryShareClass3 2025-03-31 08327861 core:RetainedEarningsAccumulatedLosses 2025-03-31 08327861 core:ShareCapital 2025-03-31 08327861 core:CurrentFinancialInstruments 2025-03-31 08327861 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 08327861 core:FurnitureFittingsToolsEquipment 2025-03-31 08327861 core:OtherPropertyPlantEquipment 2025-03-31 08327861 bus:SmallEntities 2024-01-01 2025-03-31 08327861 bus:AuditExemptWithAccountantsReport 2024-01-01 2025-03-31 08327861 bus:FilletedAccounts 2024-01-01 2025-03-31 08327861 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2025-03-31 08327861 bus:RegisteredOffice 2024-01-01 2025-03-31 08327861 bus:Director1 2024-01-01 2025-03-31 08327861 bus:Director3 2024-01-01 2025-03-31 08327861 bus:OrdinaryShareClass1 2024-01-01 2025-03-31 08327861 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-01-01 2025-03-31 08327861 bus:OrdinaryShareClass2 2024-01-01 2025-03-31 08327861 bus:OrdinaryShareClass3 2024-01-01 2025-03-31 08327861 bus:PrivateLimitedCompanyLtd 2024-01-01 2025-03-31 08327861 bus:Agent1 2024-01-01 2025-03-31 08327861 core:ComputerEquipment 2024-01-01 2025-03-31 08327861 core:FurnitureFittingsToolsEquipment 2024-01-01 2025-03-31 08327861 core:OfficeEquipment 2024-01-01 2025-03-31 08327861 core:OtherPropertyPlantEquipment 2024-01-01 2025-03-31 08327861 1 2024-01-01 2025-03-31 08327861 countries:EnglandWales 2024-01-01 2025-03-31 08327861 2023-12-31 08327861 core:FurnitureFittingsToolsEquipment 2023-12-31 08327861 core:OtherPropertyPlantEquipment 2023-12-31 08327861 2023-01-01 2023-12-31 08327861 2023-12-31 08327861 bus:OrdinaryShareClass1 2023-12-31 08327861 bus:OrdinaryShareClass2 2023-12-31 08327861 bus:OrdinaryShareClass3 2023-12-31 08327861 core:CurrentFinancialInstruments core:WithinOneYear core:PreviouslyStatedAmount 2023-12-31 08327861 core:CurrentFinancialInstruments core:PreviouslyStatedAmount 2023-12-31 08327861 core:FurnitureFittingsToolsEquipment 2023-12-31 08327861 core:OtherPropertyPlantEquipment 2023-12-31 08327861 core:PreviouslyStatedAmount 2023-12-31 08327861 bus:OrdinaryShareClass1 bus:CumulativeShares 2023-01-01 2023-12-31 08327861 bus:OrdinaryShareClass2 2023-01-01 2023-12-31 08327861 bus:OrdinaryShareClass3 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08327861

QMasters Medical Informatics Ltd

Unaudited Filleted Financial Statements

for the Period from 1 January 2024 to 31 March 2025

Pages for filing with Registrar

 

QMasters Medical Informatics Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

QMasters Medical Informatics Ltd

Company Information

Directors

Dr S L Greville-Heygate

Dr R A Greville-Heygate

Dr N Kamal

Registered office

Springfield Cottage
Long Close West
Downton
SP5 3HG

Registered number

08327861

Accountant

Corrigan Accountants Limited 1st Floor
25 King Street
Bristol
BS1 4PB

 

QMasters Medical Informatics Ltd

(Registration number: 08327861)
Balance Sheet as at 31 March 2025

Note

2025
£

2023
£

Fixed assets

 

Tangible assets

4

-

3,543

Investment property

5

-

943,704

Investments

6

51

51

 

51

947,298

Current assets

 

Debtors

7

981,196

1,249

Cash at bank and in hand

 

-

55,787

 

981,196

57,036

Creditors: Amounts falling due within one year

8

(3,966)

(10,466)

Net current assets

 

977,230

46,570

Total assets less current liabilities

 

977,281

993,868

Provisions for liabilities

(673)

(673)

Net assets

 

976,608

993,195

Capital and reserves

 

Called up share capital

9

100

100

Profit and loss account

976,508

993,095

Total equity

 

976,608

993,195

 

QMasters Medical Informatics Ltd

(Registration number: 08327861)
Balance Sheet as at 31 March 2025

For the financial period ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised for issue by the Board on 30 March 2026 and signed on its behalf by:
 

.........................................

Dr N Kamal
Director

 

QMasters Medical Informatics Ltd

Notes to the Unaudited Financial Statements for the Period from 1 January 2024 to 31 March 2025

1

Statutory information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Springfield Cottage
Long Close West
Downton
SP5 3HG
England

2

Accounting policies

Summary of significant accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention.

The financial statements are prepared in pounds sterling which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Going concern

The accounts have been prepared on a going concern basis which assumes that the company has sufficient funds to continue to trade for the foreseeable future and at least twelve months from the date of approval of these financial statements.

Disclosure of long period

The current year financial statements were prepared for the lengthened period from 1 January 2024 to 31 March 2025. The comparative amounts including the related notes are therefore not entirely comparable.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

 

QMasters Medical Informatics Ltd

Notes to the Unaudited Financial Statements for the Period from 1 January 2024 to 31 March 2025


Deferred tax
Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Fixtures and fittings

25% reducing balance

Computer equipment

25% reducing balance

Investment property

Investment property is carried at fair value, derived from the current market prices for comparable real estate determined annually by external valuers. The valuers use observable market prices, adjusted if necessary for any difference in the nature, location or condition of the specific asset. Changes in fair value are recognised in profit or loss.

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand.

Trade debtors

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are recognised at the transaction price.

 

QMasters Medical Informatics Ltd

Notes to the Unaudited Financial Statements for the Period from 1 January 2024 to 31 March 2025

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense.

The cost of any unused holiday entitlement is recognised in the period in which the employees' services are received.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 2 (2023 - 2).

 

QMasters Medical Informatics Ltd

Notes to the Unaudited Financial Statements for the Period from 1 January 2024 to 31 March 2025

4

Tangible fixed assets

Furniture, fittings and equipment
 £

Computer equipment
£

Total
£

Cost

At 1 January 2024

10,000

1,199

11,199

Disposals

(10,000)

(1,199)

(11,199)

At 31 March 2025

-

-

-

Depreciation

At 1 January 2024

6,836

820

7,656

Eliminated on disposal

(6,836)

(820)

(7,656)

At 31 March 2025

-

-

-

Carrying amount

At 31 March 2025

-

-

-

At 31 December 2023

3,164

379

3,543

5

Investment properties

2025
£

At 1 January2024

943,704

Disposals

(943,704)

At 31 March2025

-

 

QMasters Medical Informatics Ltd

Notes to the Unaudited Financial Statements for the Period from 1 January 2024 to 31 March 2025

6

Investments

2025
£

2023
£

Investments in subsidiaries

51

51


The investment represents a 51% holding in Ardens-Q Limited.

7

Debtors: amounts falling due within one year

Note

2025
£

2023
£

Amounts owed by group undertakings

981,196

716

Prepayments

 

-

533

 

981,196

1,249

8

Creditors

Note

2025
£

2023
£

Amounts falling due within one year

 

Amounts owed to group undertakings

51

51

Accruals

 

1,750

2,460

Corporation tax

 

2,165

5,583

Directors' loan accounts

 

-

2,372

 

3,966

10,466

 

QMasters Medical Informatics Ltd

Notes to the Unaudited Financial Statements for the Period from 1 January 2024 to 31 March 2025

9

Share capital

Allotted, called up and fully paid shares

 

2025

2023

 

No.

£

No.

£

Ordinary shares of £0.10 each

1,000

100.00

-

-

Ordinary A shares of £0.10 each

-

-

500

50.00

Ordinary B shares of £0.10 each

-

-

500

50.00

 

1,000

100

1,000

100


On 29 October the 500 Ordinary A shares and 500 Ordinary B shares were redesignated to Ordinary shares by special resolution.

Each share has full voting rights, entitlement to receive dividends and entitled to a return of capital in the event of a winding up of the company.

10

Dividends

 

2025
£

2023
£

Dividend of £0.10 per each Ordinary share

-

-

Dividend of £0.10 per each Ordinary A share

799,680.00

4,078,000.00

Dividend of £0.10 per each Ordinary B share

16,320.00

22,000.00

 

816,000

4,100,000